Cell and gene therapy: how can we transform artisan treatments into mass-market cures?

Cell and gene therapies are extremely effective but their complex production processes, arduous supply chain, and life-critical logistics have prevented mass market adoption. Could digitisation and AI provide a breakthrough in manufacturing? Would more companies be willing to work together on standardisation to provide more flexibility?
To find out, join us on Invent: Life Sciences, a podcast brought to you by technology and product development company TTP.
This Week's GuestsMatthew Durdy
Matthew Durdy is a biologist, investor, entrepreneur, and the Chief Executive of the Cell and Therapy Catapult. Responsible for the development of the business and strategy arm of the Cell and Gene Therapy Catapult, Matthew's work combines three sets of experience: corporate investment banking; new venture and innovation management, and biotechnology leadership, into one passion; creating the environment for, and leading the commercialisation of brilliant science into life-changing products. Alexander Seyf
Alexander Seyf is a business leader, entrepreneur, and one of the co-founders and CEO of Autolomous. Autolomous offers pragmatic digital solutions for cell and gene therapy manufacturing and was founded in 2019 with a mission to revolutionise cell and gene therapy manufacturing through digital innovation. Alexander brings a unique perspective to this endeavor, drawing from his background in physics, the telecom industry, and extensive experience in management consultancy and startups.